Related Experiment Video

Updated: Mar 3, 2026

Laparoscopic Radical Gastrectomy for Remnant Gastric Cancer
05:30

Laparoscopic Radical Gastrectomy for Remnant Gastric Cancer

Published on: October 31, 2025

287

Current status of ramucirumab in gastroesophageal adenocarcinoma

Elena Elimova1,2, Quan Lin1, Shumei Song1

  • 1Department of Gastrointestinal Medical Oncology, Medical oncology, Biostatistics, Gastroenterology, Radiation Oncology, Thoracic Oncology, Clinical Pharmacy, Pathology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd (FC10.3022), Houston, TX 77030, USA.

Future Oncology (London, England)
|April 25, 2017
PubMed

Insights

Outcomes for advanced gastric cancer remain poor. Ramucirumab, combined with paclitaxel, is now a recommended second-line treatment option for patients with advanced gastric or gastroesophageal junction adenocarcinoma.

Area of Science:

  • Oncology
  • Gastroenterology
  • Medical Research

Background:

  • Advanced gastric or gastroesophageal junction adenocarcinoma (GEAC) has poor patient outcomes.
  • Standard first-line treatment involves platinum-based chemotherapy, with limited benefit from trastuzumab in HER2-positive cases.
  • Historically, no standard second-line treatments were available for GEAC.

Purpose of the Study:

  • To review the current treatment landscape for advanced GEAC.
  • To highlight the impact of recent clinical trials on second-line therapy.
  • To discuss the emerging role of ramucirumab and future directions.

Main Methods:

  • Review of clinical trial data, including the REGARD and RAINBOW trials.
  • Analysis of treatment guidelines and recent advancements in GEAC management.
  • Discussion of the efficacy and placement of ramucirumab in the treatment paradigm.

Main Results:

  • The REGARD and RAINBOW trials established ramucirumab as a viable second-line option.
  • Paclitaxel in combination with ramucirumab is recommended for eligible patients.
  • Trastuzumab offers a modest benefit in a small subset of HER2-overexpressing GEAC patients.

Conclusions:

  • Ramucirumab has become a new standard in second-line treatment for advanced GEAC.
  • The optimal sequencing of ramucirumab may evolve with the advent of immunotherapy.
  • Continued research is crucial for improving outcomes in advanced GEAC.
Keywords:
gastroesophageal carcinomapaclitaxelramucirumab

More Related Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.4K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.3K

Related Concept Videos

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Barrett Esophagus-II: Clinical Manifestations and Management01:21

Barrett Esophagus-II: Clinical Manifestations and Management

Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
1.3K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
577
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
690
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
614